ForeSENTIA: Lung (NSCLC)

ForeSENTIA Lung NSCLC panel analyses single nucleotide variants, insertions, deletions, copy number alterations, and rearrangements in 36 genes associated with non-small cell lung cancer (NSCLC). It can help identify mutations that can be responsible for cancer development and therapy resistance in solid tumours.

According to , lung cancer is the second most common type of cancer worldwide with more than 2 million cases in 2020. NSCLC accounts for 80-85% of all lung cancer cases. There are three types of NSCLC, adenocarcinomas, squamous cell carcinoma, and large cell carcinoma which can start from different types of lung cells depending on the type. Different risk factors, such as hereditary and environmental, can contribute to NSCLC development. In addition, mutations in driver genes, including EGFR, ALK, and ROS1 among others, can lead to cancer initiation and progression. Detecting the genetic alterations that contribute to NSCLC can help in identifying FDA/EMA-approved targeted therapies and might contribute to improving the overall survival of cancer patients.

Microsatellite instability (MSI) immunotherapy biomarker can optionally be tested in this panel. FDA-approved immunotherapy drug pembrolizumab is also available for patients with MSI-high status.